Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of cevostamab + pomalidomide + dexamethasone versus investigator's choice standard therapy in relapsed/refractory multiple myeloma
MOH_2026-04-19_015775Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cevostamab in multiple myeloma (MM) (2 arms), sponsored by Roche. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2026-04-19_015775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-19_015775.